Cargando…
The effect of Mass Drug Administration for trachoma on antibodies to Chlamydia trachomatis pgp3 in children
A serologic test for antibodies to chlamydia may be a useful tool for trachoma surveillance. However, little is known about the longitudinal stability of antibody status, especially following Mass Drug Administration (MDA), which is critical to understanding serostatus in trachoma-endemic areas. A l...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7495425/ https://www.ncbi.nlm.nih.gov/pubmed/32938957 http://dx.doi.org/10.1038/s41598-020-71833-x |
_version_ | 1783582919462223872 |
---|---|
author | West, Sheila K. Munoz, Beatriz Mkocha, Harran Gaydos, Charlotte A. Quinn, Thomas C. |
author_facet | West, Sheila K. Munoz, Beatriz Mkocha, Harran Gaydos, Charlotte A. Quinn, Thomas C. |
author_sort | West, Sheila K. |
collection | PubMed |
description | A serologic test for antibodies to chlamydia may be a useful tool for trachoma surveillance. However, little is known about the longitudinal stability of antibody status, especially following Mass Drug Administration (MDA), which is critical to understanding serostatus in trachoma-endemic areas. A longitudinal cohort of 1908 children ages 1–9 years in Tanzania from 50 communities were followed at baseline and for 6 months after MDA. They were evaluated for clinical trachoma, conjunctival swabs were tested for chlamydial infection using GeneXpert platform, and blood spots were collected on filter paper and dried to test for antibodies to Chlamydia trachomatis pgp3 using the Luminex platform. 6.3% of children in the study had infection, and coverage with MDA was 97%. 670 (35%) were sero-positive for pgp3 antibodies at baseline, and 4.0% of these seroreverted to negative following MDA. Of those seronegative at baseline, 3.6% seroconverted. The individual change in log median fluorescence intensity(MFI-BG) values was -0.15 overall (p < .001). Seroconversion rates were lower following MDA and seroreversion rates were slightly higher compared to rates in this same cohort in the absence of MDA. MDA has a small effect on reduction of MFI-BG. |
format | Online Article Text |
id | pubmed-7495425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-74954252020-09-18 The effect of Mass Drug Administration for trachoma on antibodies to Chlamydia trachomatis pgp3 in children West, Sheila K. Munoz, Beatriz Mkocha, Harran Gaydos, Charlotte A. Quinn, Thomas C. Sci Rep Article A serologic test for antibodies to chlamydia may be a useful tool for trachoma surveillance. However, little is known about the longitudinal stability of antibody status, especially following Mass Drug Administration (MDA), which is critical to understanding serostatus in trachoma-endemic areas. A longitudinal cohort of 1908 children ages 1–9 years in Tanzania from 50 communities were followed at baseline and for 6 months after MDA. They were evaluated for clinical trachoma, conjunctival swabs were tested for chlamydial infection using GeneXpert platform, and blood spots were collected on filter paper and dried to test for antibodies to Chlamydia trachomatis pgp3 using the Luminex platform. 6.3% of children in the study had infection, and coverage with MDA was 97%. 670 (35%) were sero-positive for pgp3 antibodies at baseline, and 4.0% of these seroreverted to negative following MDA. Of those seronegative at baseline, 3.6% seroconverted. The individual change in log median fluorescence intensity(MFI-BG) values was -0.15 overall (p < .001). Seroconversion rates were lower following MDA and seroreversion rates were slightly higher compared to rates in this same cohort in the absence of MDA. MDA has a small effect on reduction of MFI-BG. Nature Publishing Group UK 2020-09-16 /pmc/articles/PMC7495425/ /pubmed/32938957 http://dx.doi.org/10.1038/s41598-020-71833-x Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article West, Sheila K. Munoz, Beatriz Mkocha, Harran Gaydos, Charlotte A. Quinn, Thomas C. The effect of Mass Drug Administration for trachoma on antibodies to Chlamydia trachomatis pgp3 in children |
title | The effect of Mass Drug Administration for trachoma on antibodies to Chlamydia trachomatis pgp3 in children |
title_full | The effect of Mass Drug Administration for trachoma on antibodies to Chlamydia trachomatis pgp3 in children |
title_fullStr | The effect of Mass Drug Administration for trachoma on antibodies to Chlamydia trachomatis pgp3 in children |
title_full_unstemmed | The effect of Mass Drug Administration for trachoma on antibodies to Chlamydia trachomatis pgp3 in children |
title_short | The effect of Mass Drug Administration for trachoma on antibodies to Chlamydia trachomatis pgp3 in children |
title_sort | effect of mass drug administration for trachoma on antibodies to chlamydia trachomatis pgp3 in children |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7495425/ https://www.ncbi.nlm.nih.gov/pubmed/32938957 http://dx.doi.org/10.1038/s41598-020-71833-x |
work_keys_str_mv | AT westsheilak theeffectofmassdrugadministrationfortrachomaonantibodiestochlamydiatrachomatispgp3inchildren AT munozbeatriz theeffectofmassdrugadministrationfortrachomaonantibodiestochlamydiatrachomatispgp3inchildren AT mkochaharran theeffectofmassdrugadministrationfortrachomaonantibodiestochlamydiatrachomatispgp3inchildren AT gaydoscharlottea theeffectofmassdrugadministrationfortrachomaonantibodiestochlamydiatrachomatispgp3inchildren AT quinnthomasc theeffectofmassdrugadministrationfortrachomaonantibodiestochlamydiatrachomatispgp3inchildren AT westsheilak effectofmassdrugadministrationfortrachomaonantibodiestochlamydiatrachomatispgp3inchildren AT munozbeatriz effectofmassdrugadministrationfortrachomaonantibodiestochlamydiatrachomatispgp3inchildren AT mkochaharran effectofmassdrugadministrationfortrachomaonantibodiestochlamydiatrachomatispgp3inchildren AT gaydoscharlottea effectofmassdrugadministrationfortrachomaonantibodiestochlamydiatrachomatispgp3inchildren AT quinnthomasc effectofmassdrugadministrationfortrachomaonantibodiestochlamydiatrachomatispgp3inchildren |